NanoValent Pharmaceuticals, Inc. (NVP) is an early stage oncology drug discovery and development company. Its platform technology comprises novel Targeted NanoSpheres (TNS). The lead candidate therapeutic programs have achieved both cellular and animal proof-in-concept improving efficacy and decreasing toxicity. The broader delivery platform has been functionally validated with therapeutic and diagnostic small molecule, nucleic acids, and even plasmids containing the CRISPR/Cas9 plasmid assembly for gene editing. NVP’s leading pre-clinical candidates include human CD99 targeted irinotecan (NV103) and doxorubicin (NV101) for CD positive tumors Ewing Sarcoma and Hepatocellular carcinoma and human CD19 targeted doxorubicin (NV102) for leukemia. The NV103 program is moving through GMP validation to enable IND toxicology studies for phase 1 and 2 clinical trials where resulting data should validate the potential to pursue other indications and other applications.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Montana
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Oncology
Lead Product in Development:
NV103
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
